At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
SOF/VELdrug
Likely dose
SOF/VEL 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects With Chronic HCV Infection Who Have Received a Liver Transplant
In Brief
A Phase 2 clinical trial evaluating SOF/VEL for Hepatitis C Virus Infection. Completed, enrolled 79 participants across 15 sites in 3 countries.
Detailed Summary
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir /velpatasvir (SOF/VEL) fixed-dose combination (FDC) in participants with chronic hepatitis C virus (HCV) who have received a liver transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus Infection
CountriesSpain, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartJul 2016
Primary CompletionJul 2017
TodayJul 2026
First PostedMay 24, 2016
Enrollment StartJul 27, 2016
Primary CompletionJul 28, 2017
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 10.1 years ago
Interventions
SOF/VELdrug
400/100 mg tablet administered orally once daily